Non invasive but effective

A Canadian study published in the New England Journal of Medicine concludes that chest pain in patients with heart disease could be treated as effective with medication over time as with an expensive angioplasty.

William S. Weintraub, led author of the study.
William S. Weintraub, led author of the study.
For the study, William Weintraub from Christiana Care’s John H. Ammon Chair of Cardiology and Chief of the Section of Cardiology and colleagues examined 2,287 patients with stable heart disease who received a combination of medications that possibly included aspirin, statins, nitrates, ACE inhibitors, beta-blockers and calcium channel blockers. Half of the participants also underwent angioplasties and had bare-metal stents implanted.
 
Researchers conducted a survey of about 70% of participants and found that 78% had chest pain when the study began. According to the survey, 53% of participants who underwent angioplasties reported no chest pain after three months of treatment, compared with 42% of those who only took medication. The conditions of participants in both groups continued to improve after six months of treatment, and the gap decreased, the survey found. After three years of treatment, participants in both groups reported similar levels of chest pain, quality of life and treatment satisfaction, according to the survey. Weintraub said patients' conditions improve whether they undergo angioplasties or only take medication.
 
In an editorial that accompanied the study, Eric Peterson of the Duke University Clinical Research Institute and John Rumsfeld of the Denver VA Medical Center and the University of Colorado-Denver Health Sciences Center wrote, "This study should be enlightening and practice-changing for doctors and patients alike" and should increase the use of treatment with medication for patients with stable heart disease
 
The study was funded by the U.S. Department of Veteran Affairs, the Medical Research Council of Canada and several pharmaceutical companies.
 
Photo: Christiana Care Health System
 

21.08.2008

Read all latest stories

Related articles

Photo

Endovascular brachytherapy

Endovascular brachytherapy has been successfully modified by scientists at Isotopen Technologie München AG (ITM), solving problems of radiation exposure to Rhenium-188. The researchers are now…

Photo

Gender bias

Sex-specific guidelines for cardiovascular diseases

Women are missing out on appropriate cardiac care because guidelines and medications often fail to take into account gender and conditions that specifically affect the female population. Women are…

Photo

Pediatrics

Predicting the aneurysm risk for kids with Kawasaki disease

When Olivia Nelson was 3 years old, her parents noticed that she had a fever that wouldn’t get better. They brought her to a nearby hospital, where she spent about two weeks being screened for…

Related products

Alsachim, a Shimadzu group company – Dosinaco

Clinical Chemistry

Alsachim, a Shimadzu group company – Dosinaco

Alsachim, a Shimadzu Group Company
Canon Electron Tubes & Devices – LM-Angio Tube

Accessories/ Complementary Systems

Canon Electron Tubes & Devices – LM-Angio Tube

Canon Electron Tubes & Devices Co., Ltd
IBA Dosimetry – DSA Test Device

Testing Devices

IBA Dosimetry – DSA Test Device

IBA Dosimetry GmbH
Medtron AG – Accutron HP

Injectors

Medtron AG – Accutron HP

MEDTRON AG
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH
Subscribe to Newsletter